Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion

NCT ID: NCT06968572

Last Updated: 2025-05-13

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 245 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-04-11
• Study Completion Date: 2028-05-08

Brief Summary

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK41959 when given orally in patients with MTAP Deletion locally advanced or metastatic Solid Tumors.

Detailed Description

The study will contain two phases: Phase Ia is dose escalation phase and Phase Ib is dose expansion phase.

Phase Ia will contain two part: Dose Escalation Part (Part A) and Extension Part (Part B). Part A based on the "3+3" design for dose escalation and safety evaluation requirements. Patient cohorts at selected doses may be extended to further investigate the tolerability, PK and PD of HSK41959. The number of patients to be enrolled will be up to 10 subjects in each Part B cohort. Approximately 30-50 subjects will be enrolled in Phase Ia.

Phase Ib no less than 10-50 subjects will be enrolled in each expansion cohort.

Conditions

Advanced Solid Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Phase Ia (Part A): HSK41959 as monotherapy

Phase 1a (Part A): dose escalation of HSK41959 as monotherapy at various dose levels

Group Type: EXPERIMENTAL

HSK41959

Intervention Type: DRUG

Oral administration, QD

Phase Ia (Part B): HSK41959 as monotherapy

Phase 1a (Part B): dose extention of HSK41959 as monotherapy at certain dose levels

Group Type: EXPERIMENTAL

HSK41959

Intervention Type: DRUG

Oral administration, QD

Phase Ib: HSK41959 as monotherapy

Phase 1b: dose expansion for HSK41959 as monotherapy at a dose determined during Phase 1a (Part B) in patients with MTAP Deletion locally advanced or metastatic solid tumors

Group Type: EXPERIMENTAL

HSK41959

Intervention Type: DRUG

Oral administration, QD

Interventions

HSK41959

Oral administration, QD

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years，Male and female patients, at time of signing informed consent form (ICF).

2. ECOG performance status 0-1.

3. Life expectancy ≥ 3 months.

4. Patients with locally advanced or metastatic solid tumors confirmed by histology or cytology, who have failed standard treatment (disease progression after treatment or intolerable treatment).

5. Homozygous deletion of the MTAP gene detected in tumor tissue confirmed prior to the administration of HSK41959.

6. Measurable disease by RECIST 1.1 criteria.

7. Adequate hematologic, hepatic, and renal function.

Exclusion Criteria

1. Prior treatment with a PRMT5 or MAT2A inhibitor therapy.

2. The presence of unstable, clinically symptomatic central nervous system metastases or leptomeningeal metastases.

3. Malignant tumor within 2 years, with the exception of cutaneous squamous cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma, or other tumors with low malignancy.

4. Uncontrollable pleural effusion, ascites, or pericardial effusion per protocol.

Treatment with any of the following:

5. Prior treatment with anti-tumor drug within 4 weeks or approximately 5 × t1/2 prior to the first dose of HSK41959, whichever is shorter; Prior treatment with nitrosourea or mitomycin C within 6 weeks prior to the first dose of HSK41959; Prior treatment with palliative radiotherapy or anti-tumor herbs within 2 weeks prior to the first dose of HSK41959; Prior treatment with radiotherapy, electric field therapy, or other anti-tumor therapies within 4 weeks prior to the first dose of HSK41959.

6. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment, with the exception of alopecia, dermal toxicity, and other toxicity considering no safety risks by investigator.

7. Any disease which would preclude drug absorption, metabolism or pharmacokinetics, e.g. active peptic ulcer or chronic gastroesophageal reflux disease.

8. Patients who have clinically significant or uncontrolled cardiac disease, include: QTc interval ≥ 450(male)/470(female) msec; any clinically significant arrhythmia; left ventricular ejection fraction < 50%; myocardial infarction, unstable angina, or class III/IV cardiac failure by the NYHA that occurred within 6 months prior to the first dose of HSK41959.

9. Any thromboembolic events within 6 months prior to the first dose of HSK41959; any familial or acquired thrombophilia.

10. Uncontrolled hypertension (systolic pressure≥160mmHg, or diastolic pressure≥100mmHg), diabetes (fasting blood-glucose≥10mmol/L), seizures, chronic obstructive pulmonary disease (COPD), interstitial pneumonia, pulmonary interstitial fibrosis, Parkinson's disease, active bleeding, or systemic active infection.

11. Any unstable systemic disease, e.g. severe metabolic disease: liver cirrhosis, renal failure, or uremia.

12. Patient with cognitive dysfunction, or history of mental illness, other uncontrolled comorbidities, alcohol dependence, hormone dependence or drug abuse.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

The Affiliated Hospital of Guizhou Medical University

Guiyang, Guizhou, China

Site Status: NOT_YET_RECRUITING

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, China

Site Status: RECRUITING

Shanghai East Hospital

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Facility Contacts

Chao Yu

Role: primary

yuxchao2002@163.com

86-13765021698

Yongsheng Wang

Role: primary

dolphin8012@yahoo.com

86-15150580136

Caicun Zhou

Role: primary

caicunzhoudr@163.com

86-13301825532

Other Identifiers

HSK41959-101

Identifier Type: -

Identifier Source: org_study_id